On October 20, the Engelberg Center for Health Care Reform and Friends of Cancer Research hosted the 2010 Conference on Clinical Cancer Research, where key stakeholders came together to address specific challenges in clinical cancer research and discuss potential solutions proposed by expert panels.
Panelists and participants represented the range of stakeholders in the cancer community, including senior officials from the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI), as well as thought leaders from academia, patient advocacy organizations, and the life sciences industry. FDA Commissioner Dr. Margaret Hamburg and NCI Director Dr. Harold Varmus offered keynote remarks, and four panel discussions focused on:
- Expanding the use of adaptive clinical trial design in oncology;
- Innovative and efficient pre-clinical testing;
- Incorporating pain metrics into oncology clinical trials; and
- Using patient-generated data and samples to develop evidence for targeting approved treaments.
Agenda
-
October 20
-
Welcome
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University -
Keynote Address
Harold Varmus Director, National Cancer Institute -
Panel 1: Expanding the Use of Adaptive Clinical Trial Design in Oncology
Moderator: Howard Scher Chief, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer CenterRaji Sridhara Acting Director, Division of Biometrics V - U.S. Food and Drug AdministrationRichard Simon Chief, Biometric Research Branch, National Cancer InstituteEric Rubin Deputy Assistant Secretary, European and Eurasian Affairs - U.S. State DepartmentShelley Fuld Nasso Director, Public and Medical Affairs, Susan G. Komen for the Cure -
Panel 2: Innovative and Efficient Pre-Clinical Testing
Moderator: Ken Turteltaub Executive Director, Battelle Center for Fundamental and Applied Systems Technology, Battelle Memorial InstituteJohn Leighton Associate Director for Pharmacology/Toxicology, U.S. Food and Drug AdministrationMyrtle Davis Chief, Toxicology and Pharmacology Branch, National Cancer InstituteLeigh Ann Burns-Nass DSRD Therapeutic Area Leader-Oncology, Pfizer, Inc.Adam Clark Director, Scientific and Federal Affairs, Faster Cures -
Lunch and Keynote Remarks
Introduction: Ellen Sigal Friends of Cancer ResearchMargaret Hamburg Commissioner - U.S. Food and Drug Administration -
Panel 3: Incorporating Pain Metrics into Oncology Clinical Trials
Moderator: Charles Cleeland Department Chair, Department of Symptom Research, MD Anderson Cancer CenterLaurie Burke Associate Director for Study Endpoints and Labeling Development, Office of New Drugs, U.S. Food and Drug AdministrationAnn O’Mara Head of Palliative Care Research, Community Oncology and Prevention Trials Research Group, National Cancer InstituteMartin Zagari Global Health Economics Head, AmgenCarole Baas Patient Advocate -
Panel 4: Patient Generated Samples and Data
Co-Moderator: Stephen Friend President, Sage BionetworksRichard Schilsky Chief Medical Officer - American Society of Clinical OncologyKen Buetow Director, Bioinformatics and Information Technology, National Cancer InstituteJamie Freedman Executive Vice President, R&D, GlaxoSmithKlineLaurie Fenton Ambrose President, Lung Cancer Alliance -
Summary and Closing Remarks
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
-